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ARTICLE
RNA-aptamers-in-droplets (RAPID) high-
throughput screening for secretory phenotypes
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Shuo-Fu Yuan 5, Hal S. Alper1,5 & Adam R. Abate2,3,4
Synthetic biology and metabolic engineering seek to re-engineer microbes into “living
foundries” for the production of high value chemicals. Through a “design-build-test” cycle
paradigm, massive libraries of genetically engineered microbes can be constructed and tested
for metabolite overproduction and secretion. However, library generation capacity outpaces
the rate of high-throughput testing and screening. Well plate assays are flexible but with
limited throughput, whereas droplet microfluidic techniques are ultrahigh-throughput but
require a custom assay for each target. Here we present RNA-aptamers-in-droplets (RAPID),
a method that greatly expands the generality of ultrahigh-throughput microfluidic screening.
Using aptamers, we transduce extracellular product titer into fluorescence, allowing
ultrahigh-throughput screening of millions of variants. We demonstrate the RAPID approach
by enhancing production of tyrosine and secretion of a recombinant protein in Saccharomyces
cerevisiae by up to 28- and 3-fold, respectively. Aptamers-in-droplets affords a general
approach for evolving microbes to synthesize and secrete value-added chemicals.
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M icrobes can perform chemical transformations with anease and elegance that often outclasses the best syn-thetic chemistry techniques. They operate on a chemi-
cal palette that dwarfs the diversity that is available from
petrochemicals, and they accomplish these feats in an aqueous
environment at room temperature and pressure. A major moti-
vation of synthetic biology is, thus, to re-engineer natural
microbes into “living foundries” that produce high value chemi-
cals from renewable resources. Synthetic biology embraces a
design-build-test cycle to engineer such non-native phenotypes
into microbes, for the betterment of humankind and the envir-
onment. By utilizing metabolic engineering principles, it is pos-
sible to address grand challenges, including establishing
sustainable alternatives to a fossil-fuel reliant chemical
industry1, 2. In recent years, the capacity to design and build
strains has accelerated with advances in DNA assembly and
synthesis3, 4, genome editing5–8, in vivo evolution9, 10, compu-
tational design of synthetic circuits11–13, synthetic regulatory and
perturbation systems14–17, and automation18–20. Despite these
advances, the phenotypic test step in which each variant is
assayed is a common bottleneck, often lagging by orders-of-
magnitude the throughput with which we can design and
build libraries. Consequently, there has been major investment in
the development of technologies for rapid testing of library
variants. However, traditional chromatography-reliant metabolite
detection modalities such as gas chromatography-mass spectro-
metry (GC-MS) and high pressure liquid chromatography–mass
spectrometry (HPLC-MS) are too slow without brute-force
parallelization and associated high costs. Alternative approa-
ches, such as protein-based biosensors, can link target metabolite
concentration to fluorescence or growth-selectable traits and
thus enable more rapid and efficient screening21–24. However,
biosensor development can be laborious for each new target
and often requires host-cell modifications or DNA rewiring.
Thus, new approaches for more general target detection
are required to speed the test portion of the prototyping
cycle.
A complicating challenge is that many metabolites of interest
are secreted and, thus, the production phenotype is not directly
evolvable by growth selection or flow cytometric screening. To
identify a high extracellular producer, the secreted product from
that producer must be physically isolated from that of all others,
so it can be associated to the corresponding cell. One approach is
to perform single strain assays in microtiter plates, but this is
generally limited to hundreds to thousands of strains. Droplet
microfluidic platforms shatter this barrier, as they are capable of
rapidly culturing, isolating25–28, and screening millions of cells
per hour based on secreted product titers29–33 at a fraction of the
cost of well plate methods34. Despite these advantages, however, a
critical limitation remains: product concentration must be mea-
surable via fluorescence, the only current modality with sufficient
signal to robustly detect in kilohertz flowing droplets. The vast
majority of target molecules, however, are non-fluorescent and
non-trivial to couple to a fluorescence assay, limiting droplet
screening to proof-of-principle niche applications. To enable
more effective engineering of microbes, general and high-
throughput evolution and screening strategies are needed.
In this paper, we present RNA-aptamers-in-droplets (RAPID,
Fig. 1), a general method for harnessing the power of ultrahigh-
throughput droplet screening for the enhancement of secretory
phenotypes. The core innovation of RAPID is the use of “Spi-
nach” aptamers35 to transduce secreted target molecule con-
centration into a fluorescence signal appropriate for kilohertz
droplet sorting. Aptamers are amazingly general sensors, with
hundreds of sequences reported in the literature with character-
ized binding affinity and kinetics toward analytes of biotechno-
logical interest, including small molecules and proteins36.
Quantitative dose-response relationships have also been estab-
lished for many of these aptamers35, 37. They thus provide a
general sensing technology for customizing RAPID screening of
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Fig. 1 Overview of RAPID Screening. RNA-aptamers-in-droplets (RAPID) screening uses analyte-responsive RNA aptamers grafted to the Spinach aptamer
backbone to detect analyte concentrations in microdroplets. The aptamer is co-encapsulated with a member of a yeast mutant library and incubated to
produce the molecule of interest and develop a fluorescence signal. Droplets then flow through a microfluidic device and are sorted based on fluorescence
using dielectrophoresis. Improved variants are recovered and the evolution cycle can be repeated if desired
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diverse molecular targets, by changing only the aptamer sequence.
We use RAPID screening to engineer Saccharomyces cerevisiae
strains with enhanced extracellular production of a small mole-
cule metabolite (tyrosine) and enhanced secretion of a recombi-
nant protein (streptavidin). This work establishes RAPID as a
general, high-throughput screening method for microbial strain
development, protein engineering, and synthetic biology.
Results
Design criteria for RAPID screening. RAPID is a general
approach for enhancing the production of non-fluorescent target
molecules with droplet microfluidic screening. To apply RAPID,
several conditions must be met: (i) single cells must be cultivated
in a metabolically active and productive state in picoliter droplets;
(ii) RNA aptamers must allow target concentration measure-
ments in picoliter droplets; (iii) the aptamer must remain sensi-
tive and specific even in the presence of the producer cell and
growth medium for the several day production phase; and (iv) the
microfluidic system must perform all requisite operations effi-
ciently and allow recovery of live cells for downstream cultivation
and sequencing analysis of responsible proteins or pathways.
Yeast cells proliferate and produce in microfluidic droplets.
Differentiating between cells that produce large quantities of
target molecule and those that produce little requires incubating
the cells to allow high producers to fill their droplets to a
detectable product concentration. Hence, a first condition for
RAPID is that cells must live and produce in the droplets for the
required multi-day incubation. To test the viability and pro-
ductivity of Saccharomyces cerevisiae in picoliter droplets, we
cultivated a strain producing the yellow fluorescent protein
yECitrine. The cells proliferated readily and fluoresced brightly
(Supplementary Fig. 1), thus demonstrating their metabolically
active state. This shows that the droplet environment is suitable
for multi-day yeast culture and production which will enable
droplets to be sorted based on fluorescence, validating that our
specific microfluidic platform matches previously reported cap-
abilities of microfluidic droplets29–33.
RNA aptamers sense a variety of target molecules in droplets.
The key innovation of RAPID that makes it general is the use of
Spinach-based aptamers to transduce extracellular metabolite
concentration into an optically measurable fluorescence signal35.
Spinach aptamers are a modular sensing technology consisting of
an RNA molecule that can bind an exogenous dye and target
ligand to yield a fluorescence signal. The RNA sequence can be
reprogrammed to recognize diverse targets, including amino
acids, nucleotides, and even proteins (Supplementary Fig. 2)35, 37.
Sensing aptamers can also be constructed of DNA using con-
jugation with fluorophore and quencher combinations38, but this
approach typically requires covalent modification of the aptamer.
In contrast, Spinach RNA aptamers require only a short DNA
template (100–200 bp), a commercial in vitro transcription kit,
and a commercially-available universal dye; thus, RNA aptamers
provide a general and facile assay for use in droplets. To illustrate
this concept, we created a panel of aptamers targeting an array of
small molecules and proteins (Fig. 2). In all cases, the reported
analyte-binding aptamer was grafted to the modular Spinach or
Spinach2 domain (Supplementary Fig. 2, Supplementary Table 1).
Several designs had never been attempted experimentally, and
thus we performed thermodynamic optimization using mfold39,
arriving at several candidates for testing. We then tested the best
performers from the computational screen in droplet assays. In
our first droplet tests, however, we found that aptamers per-
forming well in bulk performed poorly in droplets, particularly
when incubated with cells. We thus optimized assay conditions
for the tyrosine aptamer until we identified ones that yielded
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Fig. 2 Establishing a panel of Spinach-based aptamers that can detect analytes in droplets. A panel of Spinach-based aptamer sensors was tested across a
variety of small molecule and protein targets. Aptamers were synthesized through in vitro transcription and incubated with or without the analyte of
interest, and fluorescence was measured. Bar graphs represent the mean of three replicates (error bars depict s.d.). On the right, solutions of dye with RNA
aptamer or with both RNA aptamer and analyte were encapsulated and the resulting microdroplets were imaged using fluorescence microscopy. The
negative (RNA alone) and positive (RNA and analyte) droplets were mixed together for simultaneous imaging of contrast. All images were acquired under
the same magnification, and representative images from multiple independent trial runs are depicted. Sequences of all aptamers used in this study can be
found in Supplementary Table 1
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sensitive and stable tyrosine detection in droplets (Supplementary
Fig. 3). Under these fixed conditions, aptamers afford an amaz-
ingly general sensing modality for microfluidic droplets (Fig. 2),
providing a “plug-and-play” approach for sensing diverse target
molecules by swapping only aptamer sequence.
Aptamers sense molecules secreted by cells in droplets. During
screening, the yeast cells are cultured in droplets in a productive
metabolic state to secrete the target molecule. The secreted target
molecule, in turn, interacts with the Spinach aptamer in solution,
generating a fluorescence signal. Hence, the detection aptamer should
ideally be stable in the droplet over the several day production phase
and in the presence of cells. Otherwise, the aptamer would need to be
added after production using more advanced and less readily avail-
able microfluidic approaches such as droplet merging or picoinjec-
tion40, 41. Reliance on more complex microfluidic devices could limit
the applicability and adoption of RAPID, so we sought to achieve
stable aptamer performance in the presence of cells.
Initially, incubations of analyte and cells significantly ham-
pered aptamer signal development. To address this, we tested
blocking agents and found that 0.1 mgml−1 of double-stranded
salmon sperm DNA minimized interactions with the cell and
maintained stable aptamer signals (Supplementary Fig. 4). To
identify tyrosine-responsive aptamer variants capable of surviving
incubation with cells in droplets, we used a Spinach-tyrosine
sensor consisting of tyrosine aptamer Tyr142, the Spinach2 stem
loop backbone, and variants of a signal transducing stem. Similar
to previous Spinach biosensor development efforts that tested
7–10 variants35, we tested seven variants to identify one
(Tyr1M1) that was sufficiently sensitive, stable, and inducible
(Supplementary Fig. 5). We encapsulated this Tyr1M1 aptamer in
droplets with a panel of engineered yeast strains secreting varying
levels of tyrosine43, 44 and found that, indeed, the Tyr1M1
aptamer allowed reliable identification of strains based on their
extracellular tyrosine production. We confirmed these results by
comparing the aptamer assay with an independent chemical
derivatization assay performed on the different strains, and found
good correlation between the assays (Pearson’s r= 0.9175, p=
0.0036; Supplementary Fig. 6). This demonstrates that Tyr1M1 is
effective for differentiating between yeast cells based on tyrosine
production and, thus, can be used for ultrahigh-throughput
single-cell screening to identify high producers in a randomized
library.
Enhancing tyrosine production with RAPID evolution. Tyr-
osine and other shikimate-derived molecules have multiple uses
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Fig. 3 RAPID screening for the improvement of tyrosine production through an evolved Aro4p. The RAPID screening approach was used to identify novel
mutations in aro4 that improve tyrosine production by yeast. Libraries were constructed through mutagenizing the proposed regulatory region of Aro4p
(residues 191–263) a–c and through whole-gene mutagenesis of the best previously reported variant aro4-K229L d–f. Histograms of droplet fluorescence
pre-sort and post-sort (re-encapsulated) demonstrate enrichment through the process (a, d). Isolated and re-transformed clones randomly selected from
the pre- and post-sort populations were quantified for tyrosine production with the sorted clones having a 1.9- and 5.8-fold increase in secretion compared
to the unsorted clones for Aro4p and K229L clones, respectively (b, e). Crystal structures of Aro4p are derived from PDB 1OF6 and marked with the
identified mutations (c, f). Error bars represent standard error of biological triplicates. Tyrosine production was increased nearly 28-fold over the wild-type
production using this approach
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as polymer precursors, nutritional supplements, and therapeutic
agents, but suffer from low yields in yeast due to tight regulatory
control45. We sought to use RAPID screening to evolve a well-
characterized, feedback sensitive rate-limiting enzyme in the
pathway, the 3-deoxy-D-arabino-heptulosonate-7-phosphate
(DAHP) synthase encoded by the gene aro4. Prior work
demonstrated that several point mutations in this key enzyme,
especially K229L46, 47, reduce feedback inhibition and improve
tyrosine production47. To both de novo identify new mutations
and further improve upon the best-reported Aro4p K229L
mutant, we established two directed evolution libraries that tar-
geted: (1) specifically the regulatory region of the wild-type
protein (residues 191–263) and (2) the entire protein sequence in
the background of the K229L mutant. While this initial example
targeted aro4 for directed evolution, the RAPID approach can
also be applied to screen diversity in other genes, pathways, or
even the whole genome.
Our libraries consisted of ~ 105 mutants, which we encapsu-
lated in droplets with the Spinach-Tyr1M1 aptamer and dye, and
incubated for tyrosine production. The brightest 0.3–0.5% of
droplets were recovered via fluorescence-activated droplet sort-
ing, and the obtained mutant sequences were analyzed. Droplet
fluorescence distributions indicate significant enrichment for
improved tyrosine production post-sorting (Fig. 3a, d; Supple-
mentary Fig. 7). To confirm this, we re-transformed the sorted
and unsorted variants into a fresh yeast strain to eliminate
possible strain adaptations that may have occurred during the
process, and assayed the re-transformed clones for extracellular
tyrosine production45. The sorted variants were statistically
enriched for improved production over randomly selected
variants from the library (p< 0.05, Mann–Whitney U–test;
Figs. 3b, e). Additionally, the mean secreted tyrosine titer of
sorted clones was two (Fig. 3b) to fivefold (Fig. 3e) improved
relative to the mean titer of clones picked randomly from the
unsorted library population. The top performing variant from
each library contained novel mutations and was improved over
the best known aro4-K229L mutant. The mutant aro4-9 derived
from wild-type ARO4 (library 1) was 27-fold improved over wild-
type and has three coding mutations (H230Y, K252N, and V262I;
Fig. 3c). We investigated this variant further and determined that
the improvement is primarily driven by the novel H230Y
mutation, a residue adjacent to the reported K229 mutation
(Supplementary Fig. 8). The mutant aro4-229-9 derived from
further mutagenesis of aro4-K229L (library 2) showed a 28-fold
improvement over wild type and a 21% improvement relative to
aro4-K229L, and has two additional coding mutations (T46A and
T207I, Fig. 3f).
Importantly, while each improved enzyme possesses novel
mutations that increase tyrosine production, cell growth rate is
not affected and, thus, these variants could not have been
enriched for and discovered via growth selections (Supplementary
Fig. 9). Furthermore, because it has not been previously possible
to screen for the impact of aro4 in a secretion pathway in a high-
throughput format, all identified mutations were previously
unknown. Indeed, previous efforts to enhance aro4 relied on
hypotheses based on crystal structures and understandings of
protein dynamics46, approaches that are not always possible or do
not always yield the optimal structure, particularly if the enzyme
to be evolved is difficult to crystallize, poorly understood, or
embedded in a multi-component pathway. The RAPID approach
is thus a powerful alternative because it allows discovery of
unknown and unpredictable mutations in an unbiased manner.
Enhancing streptavidin secretion with RAPID screening. To
illustrate the generality of the RAPID screening approach and
aptamer sensing, we used RAPID to enhance a different pheno-
type; the secretion of a recombinant protein via secretory tag
directed evolution. Despite the markedly different biological
objective of this screen, the RAPID process is virtually unchanged
except in the aptamer ligand-binding domain, further illustrating
the flexibility of the method. As a model recombinant protein
target, we used streptavidin, a well-characterized protein derived
from Streptomyces avidinii that binds with high affinity and
specificity to biotin and peptide affinity tags48, 49 and has wide-
ranging biotechnological applications50–54.
Previous attempts for optimizing heterologous expression of
full-length streptavidin have been conducted in bacteria such as
E. coli or B. subtilis55, 56 and in the yeasts Saccharomyces
cerevisiae or Pichia pastoris57, 58 achieving titers of up to
62 mg l−1 in P. pastoris after clone screening and optimization57.
To secrete protein in S. cerevisiae, a secretion tag is required and,
thus, we use RAPID to evolve the commonly used α-mating
factor secretory leader (αMF). Mutants of this sequence have been
investigated for improving secretion of antibody fragments
(scFv)59, but the screening process required a complex chemical
conjugation to alter the cell surface and was dependent on
antibody binding. By contrast, RAPID screening requires no
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chemical modification of production cells and is not dependent
on properties of the secreted recombinant protein. These
advantages allow evolutionary selection that better co-evolves
secretion signal and target protein, a linkage that has previously
been hypothesized as being critical59.
For this example, we generated a mutant library of the αMF
secretion signal fused to streptavidin and transformed the
resulting plasmid population into yeast. We then encapsulated
and cultivated the library, using the Spinach-streptavidin aptamer
for quantitation. We observed differences in streptavidin-induced
fluorescence after 3 days, with a fully matured signal after five
(Supplementary Fig. 10). We then sorted the library after 5 days
of incubation, recovering the brightest 0.1% of droplets. To assess
the screen, we re-encapsulated the sorted and unsorted libraries,
and incubated and analyzed them with the same droplet
fluorescence detector. The sorted pool exhibited a broad range
of production phenotypes, with many variants exhibiting higher
production than wild type (Fig. 4a). After re-transforming
individual randomly selected variants from the sorted and
unsorted populations into a fresh yeast strain, we measured
streptavidin titer in supernatant samples from shake-flask
production cultures and found that two of the seven variants
isolated by droplet sorting have significantly increased secretion
(p< 0.01, One-way analysis of variance (ANOVA) with Dunnett’s
Test for multiple comparisons to WT control). We observed up to
threefold higher supernatant streptavidin titer compared to the
wild-type αMF construct and found that some mutant αMF
secretory leader sequences align with previously reported
mutations (Supplementary Fig. 11), with the highest performers
exhibiting a nonpolar to polar mutation (I→ T) in the LLFI
motif59. In contrast, we were unable to obtain any improved
mutants by randomly isolating variants from the unsorted library
population. This serves as another example illustrating the
efficacy and generalizability of RAPID for evolving enhanced
secretion phenotypes.
Discussion
We have demonstrated a generalizable approach for enhancing
secretory phenotypes for small molecules and proteins with
droplet microfluidic evolution. Our approach addresses a pre-
viously unmet need in the design-build-test cycle: the efficient
testing of large secretion libraries in a format that is generalizable
across diverse molecular targets. A key innovation of RAPID is
implementation of Spinach RNA aptamers as general readouts for
target molecule titers, which enables ultrahigh-throughput dro-
plet assays. Indeed, aptamers are useful for a broad range of
applications and are employed throughout biology. RAPID
leverages this infrastructure, allowing facile construction of bio-
sensors against new targets using published binding sequences.
When no RNA aptamer sequences are available for a given target,
systematic evolution of ligands by exponential enrichment
(SELEX) can generate them60. Other extracellular biosensors,
such as DNA aptamers38, should also be usable in our screening
workflow.
A unique and valuable feature of RAPID is that it is gentle and
thus capable of maintaining the secreting cells in a live and
productive state for days. While this initial work focused on
screening yeast libraries for enhancing extracellular metabolite or
recombinant protein titers, other cell types and screening
goals have been addressed using similar microfluidic sorting
devices33, 61–63, suggesting a wide range of potential applications
for our aptamer-based approach. In addition, RAPID screening
yields live cells after sorting, which can be cultured or analyzed to
directly recover mutational enhancements. This enables new
opportunities in which in vivo mutagenesis techniques10 are
combined with RAPID to obviate manual in vitro library gen-
eration. We envision a future in which this strategy allows design,
build, and test phases to be cycled continuously without human
intervention, employing automation to iterate between in vivo
mutagenesis and microfluidic screening to evolve a human-
defined trait of interest.
Methods
Microfluidic device fabrication. Soft lithography and device design (Supple-
mentary Fig. 12) were performed using procedures described by Xia and White-
sides64. In brief, a layer of photoresist was spun onto silicon wafers and UV etched
using a high resolution mask. The etched wafer was placed into developer solution
and dried before pouring PDMS. Inlets into the embossed PDMS device were
punched using a 0.75 mm biopsy tool and were attached to a glass slide using
plasma bonding. Hydrophobicity was applied to the channels using aquapel
(Pittsburgh Glass Works).
Construction and testing of metabolite-binding RNA aptamers. To construct all
RNA sensors, synthetic double-stranded DNA sequences (gBlocks) were obtained
from IDT, incorporating the Spinach sequence with the metabolite-binding apta-
mer inserted into a stem loop segment35, as well as a T7 promoter sequence
allowing transcription of the appropriate sequence (Supplementary Table 1). RNA
was produced using the Ampliscribe T7-flash in vitro transcription kit using a
gBlock as a template (Integrated DNA Technologies). RNA aptamers were purified
by chloroform extraction using ammonium acetate.
To measure sensor fluorescence, RNA was diluted to 10 μM in 50mM Tris-
HCl, pH 7.5, 125 mM KCl, 5 mM MgCl2, and heat denatured at 95 °C for 3 min. It
was then incubated at 37 °C for 1–2 h to allow proper folding. Finally, DFHBI or
DFHBI-1T (Lucerna) was added to a final concentration of 2 μM, and the ligand
was added to a final concentration of 1 mM except thrombin and streptavidin
where 2.7 and 1.7 μM were used, respectively. Fluorescence was measured
continuously after addition of the metabolite with an excitation wavelength of 460
nm and an emission wavelength of 500 nm for DFHBI, or with excitation of 482
nm and emission of 510 nm for DFHBI-1T.
Testing Spinach sensors in microfluidic droplets. RNA spinach sensors, dyes,
and ligands were encapsulated with droplet generation device with flow rate of 200
μl h−1 for both aqueous and oil phases. Fluorescence images of incubated micro-
fluidic droplets were captured with a Zeiss Axiovert microscope (10×/0.3 Plan-
NEOFLUAR objective and Zeiss FluoArc) and processed by AxioVision SE64 Rel
4.0.1.
Growth and transformation procedures for E. coli and yeast. Yeast expression
vectors were propagated in E. coli DH10β. E. coli strains were routinely cultivated
in LB medium (10 tryptone, 5 yeast extract, and 10 g l−1 sodium chloride)
(Teknova) at 37 °C with 225 RPM orbital shaking. LB was supplemented with 100
µg ml−1 ampicillin (Sigma) when needed for plasmid maintenance and propaga-
tion. Yeast strains for which maintenance of auxotrophic markers was unnecessary
were propagated in YPD (10 yeast extract, 20 peptone, 20 g l−1 glucose). When
required for plasmid maintenance, yeast strains were cultivated on a yeast synthetic
complete (YSC) medium containing 6.7 g of Yeast Nitrogen Base (Difco) per l−1,
20 g glucose per l−1 and a mixture of appropriate nucleotides and amino acids
(CSM, MP Biomedicals, Solon, OH). For YSC medium containing galactose, glu-
cose was omitted from the above recipe and replaced with 20 g l−1 galactose. All
components were supplemented with 2% agar for solid media.
For E. coli transformations, 25 µl of electrocompetent E. coli DH10β were mixed
with 30 ng of ligated or Gibson-assembled DNA and electroporated (2 mm
Electrporation Cuvettes (Bioexpress) with Biorad Genepulser Xcell) at 2.5 kV.
Transformants were rescued for one hour at 37 °C in 1 ml SOC Buffer (Cellgro)
plated on LB agar and incubated overnight. Single clones were amplified in 5 ml LB
medium and incubated overnight at 37 °C. Plasmids were isolated (QIAprep Spin
Miniprep Kit, Qiagen) and confirmed by Sanger sequencing.
For yeast transformations, 50 µl of chemically competent S. cerevisiae BY4741
(ATCC® 4002900) were transformed with 1 µg of each appropriate purified
plasmid according to established protocols65, plated on the appropriate medium,
and incubated for 3 days at 30 °C. Multiple transformations were performed as
needed to generate libraries of sufficient size for directed evolution. Single colonies
were picked into 1 ml of the appropriate medium and incubated at 30 °C. Plasmids
were isolated from yeast using a Zymoprep Yeast Miniprep Kit II (Zymo
Corporation) and transformed into E. coli for further amplification.
Molecular cloning procedures. PCR reactions were performed with Q5 Hot-Start
DNA Polymerase (NEB) according to manufacturer specifications. Digestions were
performed according to manufacturer’s (NEB) instructions, with digestions close to
the end of a linearized strand running overnight and digestions of circular strands
running for 1 h at 37 °C. PCR products and digestions were purified with a
QIAquick PCR Purification Kit (Qiagen). Phosphatase reactions were performed
with Antarctic Phosphatase (NEB) according to manufacturer’s instructions and
heat-inactivated for 15 min at 65 °C. Ligations (T4 DNA Ligase, Fermentas) were
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performed overnight at 22 °C followed by heat inactivation at 65 °C for 20 min.
Plasmids were also made using Gibson Assembly (NEB), by mixing PCR products
with the enzyme mixture and heating to 50 °C for 1 h. Ligations and Gibson-
assembled plasmids were then transformed into E. coli DH10β and plated. Indi-
vidual colonies were then amplified in liquid culture and plasmids were extracted.
Correctly assembled plasmids were confirmed through restriction digestion and
sequencing.
Directed evolution for tyrosine over-production. Two libraries were made for
the evolution of aro4: one derived from the wild-type gene and one from the K229L
mutant, which has been shown to exhibit lower feedback inhibition47. Each gene
was PCR amplified in an error-prone manner using GeneMorph II kit (Agilent)
following the protocol for “medium” error-rate (4.5–9 errors per kbp). The
amplified product was purified using gel extraction, then digested and cloned into a
backbone plasmid as described above. The mutant plasmid libraries (ranging from
~ 5 × 104 to 1 × 105 in size) were then transformed into E. coli DH10-β using
electroporation, which were then harvested from petri dishes. The plasmid libraries
were then purified and transformed into a strain of yeast with aro3 and aro4 (both
of which encode DAHP synthase activity) knocked out43. After transformation, the
yeast libraries were grown to stationary phase and glycerol stocked.
Each library was then individually grown to saturation from frozen stock in the
appropriate YSC dropout media over 2–3 days. Cells were then diluted by mixing
in 100 mM Tris (pH 7.5), 200 mM KCl, 10 mM NaCl, 10 mM MgCl2, 30 μM RNA
aptamer, 3 μM DFHBI-1T (Lucerna, Inc.), and 0.1 mgml−1 of double-stranded
salmon sperm DNA (Thermo Fisher) to a final cell density of 0.3. For streptavidin
library we used 10 μM RNA aptamer and 1 μM DFHB1-1T. At this concentration
of cells and size of droplets (40 μm), this results in ~1 in 10 droplets containing a
single cell and 1 in 100 containing two cells, which may increase sorting false
positives and thus affect sorting efficiency. This culture was then encapsulated in
droplets and incubated at room temperature for 48 h prior to sorting.
To detect and sort microfluidic droplets using a fluorescence signal, we made
use of a custom built fluorimeter and microscope. As droplets flow through the
microfluidic channel, they are exposed to a 473 nm laser to excite individual
droplets and the emission is measured using a PMT with a 517 nm bandpass filter.
LabVIEW (National Instruments) software with a user set threshold for sorting
controlled a field programmable gate array card to apply a voltage to a high voltage
amplifier (Teck) to dielectrophoretically move the droplet into the sorted outlet
while unsorted droplets continue unperturbed. After sorting, droplets were opened
using perfluorooctanol and collected cells were cultured in dropout media for
several days, at which point samples were either re-encapsulated in droplets for
comparison to the pre-sort population or frozen for further assays.
Post-sort, total DNA from post-sort cultures were extracted (Zymo) and re-
transformed to E. coli. Simultaneously, the original library was grown from glycerol
stock and the same DNA extraction and transformation were carried out. Next,
individual clones were picked from each, followed by plasmids isolation and
sequencing. Those plasmids encoding mutations were re-transformed into a fresh
strain of yeast containing the same double knockout of aro3 and aro4. This strategy
eliminates any possible strain adaptation that may account for high-production.
Assaying aromatic amino acid production of cell cultures. Cells were pre-
cultured in YSC dropout media for at least 2 days. The OD600 was measured, and
each culture was centrifuged, washed with water, and finally diluted to OD600= 3
with minimal media, which contains 20 glucose, 20 methionine, 12 adenine, 20
uracil, 20 histidine, and 100 mg l−1 leucine. Cells were incubated at 30 °C in this
media for 2 additional days, and then centrifuged to pellet. The media supernatant
was then measured using a tyrosine derivatization assay. 100 μl of supernatant was
mixed with an equal volume of solution containing 0.05% (w/v) 1-nitroso-2-
naphthol, 50% ethanol, 10% (v/v) nitric acid and 0.25 g l−1 (w/v) NaNO2. The
reaction was catalyzed by incubating at 55 °C for 45 min, then read by fluorescence
using an excitation of 485 nm and emission of 590 nm45. A standard curve of
tyrosine was used to quantify. Correlation between culture supernatant tyrosine
concentration (measured using this assay) and corresponding Tyr1M1 aptamer
fluorescence was analyzed using GraphPad Prism 6 (Pearson r determination,
α= 0.05 for significance).
Characterization of exponential growth rates. Maximum rates of exponential
growth were characterized for cells expressing mutant aro4 genes using a Bioscreen
C (Growth Curves USA). Briefly, selected strains were inoculated into the appro-
priate media, either complete (YSC-Histidine) or minimal (20 glucose, 20
methionine, 12 adenine, 20 uracil, and 100 mg l−1 leucine), at OD600 = 0.1 and
OD600 measurements were taken every 15 min using continuous shaking for
3 days at 30 °C. Growth rates were calculated using a custom MATLAB script
(available upon request).
Directed evolution for streptavidin secretion. The alpha mating factor (αMF)
secretion signal from S. cerevisiae was fused to full-length streptavidin (SA,
including PDB 2BC3_A residues 12-159) and codon optimized for S. cerevisiae
expression as a gBlock (Integrated DNA Technologies). SA was PCR amplified and
cloned into p426-GAL166 to yield p426-GAL1-SA. The αMF sequence was then
mutated (full length except ATG start codon) using nucleotide analog mutagenesis
(NAM) according to the general dNTP/8-oxo-dGTP (Trilink) protocol described
by Zaccolo et al.67. Specifically, 20 μM of nucleotide analogs was used in a reaction
with Taq polymerase (NEB) with a varying number of PCR cycles (12–30 cycles).
The mutated PCR product was then amplified using Q5 High Fidelity Polymerase
(NEB) and the same primers in order to clear the nucleotide analogs and amplify
sufficient DNA for Gibson assembly4. The resulting PCR product was then com-
bined with PCR linearized acceptor vector p426-GAL1-SA in 10 standard Gibson
assembly reactions to yield the plasmid library/pool p426-GAL1-αMF[NAM]-SA.
This library was then transformed into electrocompetent DH10β in 25 transfor-
mations to yield a library size of ~5 × 106 variants. After MaxiPrep (Zymo) to
recover the plasmid library from E. coli, the library was transformed into S. cere-
visiae BY4741 using the standard lithium acetate transformation protocol. This
yielded an estimated yeast library size of 1–3 × 106 variants based on fractional
plating and colony counting on YSC-Ura + Glucose selective plates. A sample of
the unsorted/pre-sort library was subjected to yeast MiniPrep (Zymo), and the
unsorted pool was transformed into electrocompetent DH10β for recovery and
Sanger sequencing of seven clonal colonies. This same procedure (yeast MiniPrep,
DH10β transformation, E. coli MiniPrep, Sanger sequencing of) was also used to
later isolate individual sequences from seven clonal colonies derived from the
RAPID sorted pool. RAPID sorting was performed as described above for tyrosine
directed evolution. After sorting, droplets were opened using perfluorooctanol and
collected cells were cultured in dropout media for several days, at which point
samples were either re-encapsulated in droplets for comparison to the pre-sort
population or frozen for further assays.
High-copy episomal 2μ plasmids (p426-GAL1 based) bearing individual mutant
αMF sequences or sequence pools (unsorted and sorted) were re-transformed into
fresh S. cerevisiae BY4741 cells using the Frozen EZ II Transformation Kit (Zymo)
according to the manufacturer’s protocol scaled down to 96-well plate format: 20 μl
cells (pre-frozen), 2 μl plasmid DNA, and 200 μl EZ III Buffer per well. The wild-
type αMF-SA plasmid (WT, no mutagenesis), a negative control plasmid (p426-
GAL1 with no streptavidin gene), the unsorted plasmid pool, and the sorted
plasmid pool were also re-transformed at the same time to act as controls/
comparators for the individual clone sequences. After plating each transformation
mixture on YSC-Ura + Glucose for selection, three colonies were picked from each
plate (biological triplicate) into 1 ml of liquid YSC-Ura media containing glucose
for cell outgrowth and glycerol stocking in 96-deepwell blocks. Starter cultures
were then inoculated from glycerol stocks into 2 ml of YSC-Ura + Glucose for
3 days of growth at 30 °C in 14-ml culture tubes in a rotating roller drum. All 2 ml
of culture was then added to 58 ml of YSC-Ura + 2%Glucose, and the 60 ml
cultures were incubated in 250-mL shake flasks at 225 RPM/30 °C for 4 days (final
OD600= 5–7). Sufficient cells to seed 30 ml cultures at OD600= 10 were spun
down at 500 x g for 10 min, then re-suspended in 25 ml of YSC-Ura + 4%Galactose
to induce protein production at 225 r.p.m./30 °C in a shaking incubator for 5 days.
20 ml of supernatant was then harvested by gentle centrifugation (500×g for 10
min) and an equal volume of saturated ammonium sulfate solution (~ 4.32 M,
sterile filtered to remove excess solid) was added to precipitate the secreted
streptavidin overnight at 2–8 °C. After centrifugation at 15,000×g for 1 h at 4 °C,
the resulting precipitated protein pellet was re-suspended until visibly
homogeneous in 4 ml of Corning DPBS (i.e., 5× concentration relative to
production culture volume) and allowed to rehydrate overnight at 2–8 °C in DPBS
buffer before assay. Reported concentrations are corrected for 5× concentration
factor in purification and represent titer in the culture supernatant.
The Spinach2-Streptavidin aptamer was ordered as a synthetic DNA gBlock
(Integrated DNA Technologies). Aptamer RNA was then prepared in a similar
manner to the previously described tyrosine aptamer. Briefly: the Spinach2-
Streptavidin biosensor sequence was PCR amplified with a primer set to add an
upstream T7 promoter for in vitro transcription. The resulting PCR product was
purified by spin column (Thermo Scientific) and used as a template for in vitro T7
transcription using the AmpliScribe T7-Flash Transcription kit (Epicentre)
according to the manufacturer protocol. Pure RNA was isolated by standard
ethanol precipitation. 1, 5, 10, 20, 30, 40, 50, 60 and 100 mg l−1 of streptavidin
standard (NEB) were chosen as standard curve points (Supplementary Fig. 13). To
make a standard curve sample, streptavidin stock (100 mg l−1) was diluted directly
in 1× DPBS (Corning) to the target concentration. Secreted streptavidin samples
from cultures were ammonium sulfate precipitated and re-suspended in DPBS
before assay. Each sample (standard curve point or re-suspended sample) was
mixed with a solution of 10 μM Spinach2-Streptavidin aptamer and 2 μM DFHBI-
1T (Lucerna, Inc.) and incubated at 25 °C for 14 h in a buffer containing 100 mM
Tris, pH 7.5, 200 mM KCl, 10 mM NaCl and 1 mM MgCl2. Total volume of
reaction was 100 μl and the fluorescence assay was carried out in a black wall 96-
well microtiter plate (Thermo). Fluorescence measurements were performed using
a Cytation3 imaging reader (BioTek) using the following instrument parameters:
excitation wavelength= 482 nm, emission wavelength= 510 nm, gain= 100, read
height = 7 mm. The secreted streptavidin concentration in yeast production
cultures was determined based on a linear regression of the standard curve from
1–40 mg l−1 (all tested samples fell in this range of fluorescence signal) and by
correcting for a 5× concentration factor from protein precipitation. Statistical
analysis of mutants was performed using GraphPad Prism 6 (one-way ANOVA
with Dunnett’s Test for multiple comparisons to the WT control). A test for equal
variances was performed (GraphPad Prism 6) to confirm that variances were not
significantly different prior to proceeding with One-way ANOVA and Dunnett’s
Test.
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